A project that shows significant promise as a next generation treatment for malaria
MMV has awarded its coveted Project of the Year 2009 to Spiroindolones, a project that shows significant promise as a next generation treatment for malaria. The award is well-deserved as the Spiroindolone class of compounds have not only shown favourable physical and chemical properties for drug development, but most importantly have also exhibited a rapid ability to kill the blood-stages of both P. falciparum and P. vivax. The compound NITD609 is part of this compound class, a new chemical entity identified from the compound library at the Novartis Institute for Tropical Diseases, and has demonstrated great antimalarial potential.
Image provided by GNF Systems